Use of time-density curves of dynamic contrast-enhanced computed tomography for determination of the histological therapeutic effects of neoadjuvant chemotherapy for pancreatic ductal adenocarcinoma

被引:2
作者
Goto, Shintaro [1 ]
Yoshizawa, Tadashi [1 ]
Ishido, Keinosuke [2 ]
Seino, Hiroko [3 ]
Morohashi, Satoko [1 ]
Ogasawara, Hirokazu [2 ]
Kubota, Shunsuke [2 ]
Ogasawara, Kenta [2 ]
Nakamura, Akie [2 ]
Hakamada, Kenichi [2 ]
Kijima, Hiroshi [1 ]
机构
[1] Hirosaki Univ, Grad Sch Med, Dept Pathol & Biosci, 5 Zaifu Cho, Hirosaki, Aomori 0368562, Japan
[2] Hirosaki Univ, Grad Sch Med, Dept Gastroenterol Surg, Hirosaki, Aomori 0368562, Japan
[3] Aomori Natl Hosp, Dept Radiol, Namioka, Aomori 0381338, Japan
基金
日本学术振兴会;
关键词
pancreatic cancer; PDAC; TDC; dynamic CECT; NAC; histological therapeutic effect; ART; MICROVESSEL DENSITY; CANCER; GEMCITABINE; BORDERLINE; SURVIVAL; FOLFIRINOX; TUMORS;
D O I
10.3892/or.2023.8498
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The present study aimed to investigate the histological changes caused by neoadjuvant chemotherapy (NAC) for pancreatic ductal adenocarcinoma (PDAC), and to demonstrate the use of time-density curves (TDCs) of dynamic contrast-enhanced computed tomography (CECT) for determination of the histological therapeutic effects of NAC for PDAC. A total of 96 patients with PDAC were examined; 46 underwent NAC (NAC group) and 50 did not undergo NAC (non-NAC group). Based on histological therapeutic effect and using the area of residual tumor (ART) grading system, the NAC group was divided into low-responders and high-responders. Histological analysis was used to evaluate the densities of cancer cells, cancer-associated fibroblasts (CAFs), microvessels and stromal collagen fibers in the NAC and non-NAC groups. Radiological analysis was used to evaluate the TDCs of three slopes of the NAC group, namely slopes between the non-contrast and arterial phases (delta 1 and delta 1 '), between the arterial and portal phases (delta 2 and delta 2 '), and between the portal and equilibrium phases (delta 3 and delta 3 '). delta 1-delta 3 were before NAC, whereas delta 1 '-delta 3 ' were after NAC. Changes in delta 1, delta 2 and delta 3 before and after NAC were denoted as delta delta 1 (=delta 1 '-delta 1), delta delta 2 (=delta 2 '-delta 2) and delta delta 3 (=delta 3 '-delta 3). ART grading system, histological examination and radiological examination data were also statistically analyzed. Histological examination revealed a significant decrease in cancer cells and CAFs, and a significant increase in stromal collagen fibers due to NAC (P<0.01). Radiological examination revealed that delta 1 ' was significantly higher than delta 1 in low-responders (P<0.05), whereas delta 2 ' was significantly lower than delta 2 in high-responders (P<0.01). delta delta 2 was significantly lower and delta delta 3 was significantly higher in high-responders than in low-responders (P<0.01 and P<0.05, respectively). Receiver operating characteristic curve showed that delta delta 2 and delta delta 3 were effective indicators of the histological therapeutic effect of NAC. In conclusion, the TDC of dynamic CECT may be useful for determining the histological therapeutic effect of NAC for PDAC.
引用
收藏
页数:11
相关论文
共 34 条
  • [1] FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma
    Abdelrahman, Amro M.
    Goenka, Ajit H.
    Alva-Ruiz, Roberto
    Yonkus, Jennifer A.
    Leiting, Jennifer L.
    Graham, Rondell P.
    Merrell, Kenneth W.
    Thiels, Cornelius A.
    Hallemeier, Christopher L.
    Warner, Susanne G.
    Haddock, Michael G.
    Grotz, Travis E.
    Tran, Nguyen H.
    Smoot, Rory L.
    Ma, Wen Wee
    Cleary, Sean P.
    McWilliams, Robert R.
    Nagorney, David M.
    Halfdanarson, Thorvardur R.
    Kendrick, Michael L.
    Truty, Mark J.
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2022, 20 (09): : 1023 - +
  • [2] Role of bevacizumab in neoadjuvant chemotherapy and its influence on microvessel density in rectal cancer
    Arimoto, Atsuki
    Uehara, Keisuke
    Tsuzuki, Toyonori
    Aiba, Toshisada
    Ebata, Tomoki
    Nagino, Masato
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2015, 20 (05) : 935 - 942
  • [3] Awai K., 2011, NICHIDOKU IHO, V56, P13
  • [4] Brierley JD., 2017, TNM CLASSIFICATION M, V93, P95
  • [5] Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
    Burris, HA
    Moore, MJ
    Andersen, J
    Green, MR
    Rothenberg, ML
    Madiano, MR
    Cripps, MC
    Portenoy, RK
    Storniolo, AM
    Tarassoff, P
    Nelson, R
    Dorr, FA
    Stephens, CD
    VanHoff, DD
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) : 2403 - 2413
  • [6] Perineural and Intraneural Invasion in Posttherapy Pancreaticoduodenectomy Specimens Predicts Poor Prognosis in Patients With Pancreatic Ductal Adenocarcinoma
    Chatterjee, Deyali
    Katz, Matthew H.
    Rashid, Asif
    Wang, Hua
    Iuga, Alina C.
    Varadhachary, Gauri R.
    Wolff, Robert A.
    Lee, Jeffrey E.
    Pisters, Peter W.
    Crane, Christopher H.
    Gomez, Henry F.
    Abbruzzese, James L.
    Fleming, Jason B.
    Wang, Huamin
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2012, 36 (03) : 409 - 417
  • [7] Calvi END, 2012, ACTA CIR BRAS, V27, P681
  • [8] Microvessel density and endothelial cell proliferation levels in colorectal liver metastases from patients given neo-adjuvant cytotoxic chemotherapy and bevacizumab
    Eefsen, Rikke Lovendahl
    Engelholm, Lars
    Willemoe, Gro L.
    Van den Eynden, Gert G.
    Laerum, Ole Didrik
    Christensen, Ib Jarle
    Rolff, Hans Christian
    Hoyer-Hansen, Gunilla
    Osterlind, Kell
    Vainer, Ben
    Illemann, Martin
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2016, 138 (07) : 1777 - 1784
  • [9] Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer
    Ferrone, Cristina R.
    Marchegiani, Giovanni
    Hong, Theodore S.
    Ryan, David P.
    Deshpande, Vikram
    McDonnell, Erin I.
    Sabbatino, Francesco
    Santos, Daniela Dias
    Allen, Jill N.
    Blaszkowsky, Lawrence S.
    Clark, Jeffrey W.
    Faris, Jason E.
    Goyal, Lipika
    Kwak, Eunice L.
    Murphy, Janet E.
    Ting, David T.
    Wo, Jennifer Y.
    Zhu, Andrew X.
    Warshaw, Andrew L.
    Lillemoe, Keith D.
    Fernandez-del Castillo, Carlos
    [J]. ANNALS OF SURGERY, 2015, 261 (01) : 12 - 17
  • [10] nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
    Goldstein, David
    El-Maraghi, Robert Hassan
    Hammel, Pascal
    Heinemann, Volker
    Kunzmann, Volker
    Sastre, Javier
    Scheithauer, Werner
    Siena, Salvatore
    Tabernero, Josep
    Teixeira, Luis
    Tortora, Giampaolo
    Van Laethem, Jean-Luc
    Young, Rosemary
    Penenberg, Darryl Neil
    Lu, Brian
    Romano, Alfredo
    Von Hoff, Daniel D.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2015, 107 (02):